Drug Profile
Research programme: calpain inhibitors - Teva Pharmaceutical Industries
Latest Information Update: 27 Oct 2011
Price :
$50
*
At a glance
- Originator Cephalon
- Class
- Mechanism of Action Calpain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 26 Mar 2007 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 15 Dec 2003 No development reported - Preclinical for Stroke in USA (unspecified route)
- 04 Jun 2002 This programme is still in active development